Shilpa Medicare’s equal joint venture with Zydus group - Oncosol - along with its partner company Shorla Oncology, has announced USFDA's approval for IMKELDI, the first oral liquid form of imatinib to treat certain forms of cancers, the company said on November 27.
IMKELDI is a liquid formulation of cancer drug imatinib, and can help slow or prevent the growth of specific types of cancers and gastrointestinal tumors (GIST). Despite proven clinical benefits of imatinib, patient adherence was an issue, said Shilpa Medicare, underscoring the need for a oral solution delivery system.
“Oral solutions may ensure more precise and consistent dosing, offering a convenient alternative to compounding for patients who have difficulty swallowing or require dosing tailored to body surface area,” Sharon Cunningham, chief executive officer of Shorla said in a separate press release.
The company recently posted strong September quarter results, clocking a consolidated net profit rise of 28 percent sequentially, and an 1014 percent on-year to Rs 18 crore. Revenue from operations rose 17.5 percent on-quarter and 10 percent on-year to Rs 344 crore. Shilpa Medicare saw eight consecutive quarters of sequential improvement in EBITDA. Read More
The H1FY25 revenue growth was majorly driven by emerging markets as well as licensing in formulation segment and biological business.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
